Evaluation of the analgesic effect of subcutaneous methadone after cesarean section

Background: Inadequate pain control has a significant role in maternal and neonatal health in early post-partum period which interferes with breastfeeding and has a negative influence on child normal growth. The aim of this study is evaluation of subcutaneous methadone effectiveness on post-operative pain control. Materials and Methods: Double blind randomized prospective clinical trial involving 60 term pregnancy patients through 2008 to 2009 Undergo cesarean. Inclusion criteria: Prime gravid candidate of elective cesarean and spinal anesthesia class 1 or 2. Known case of drug allergy and methadone interaction, addiction, uncontrolled medical disease excluded. Case group injected 10 mg of subcutaneous methadone in the site of incision before final suture. Morphine was a pain reliever in follow up examination. Data include mean of pain, nausea and vomiting, MAP, etc., collected and analyzed by independent-T test and Man Whitney test. Results: Although mean usage of morphine between groups was not significant statistically but the mean pain severity (P value < 0.05) and mean satisfactory (P value = 0.02) was statistically significant between groups. Other parameters were not statistically significant. Conclusion: We suggest subcutaneous methadone as a safe pain reliever in post cesarean section patients.

[1]  R. Fainsinger,et al.  Subcutaneous methadone--an issue revisited. , 2007, Journal of pain and symptom management.

[2]  A. Leung Postoperative pain management in obstetric anesthesia--new challenges and solutions. , 2004, Journal of clinical anesthesia.

[3]  S. Fishman,et al.  Methadone reincarnated: novel clinical applications with related concerns. , 2002, Pain medicine.

[4]  E. Bruera,et al.  Methadone use in cancer patients with pain: a review. , 2002, Journal of palliative medicine.

[5]  K. Ilett,et al.  Distribution of R- and S-methadone into human milk during multiple, medium to high oral dosing. , 2001, British journal of clinical pharmacology.

[6]  Y. Shir,et al.  Methadone is safe for treating hospitalized patients with severe pain , 2001, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[7]  E. Bruera,et al.  Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. , 1999, Journal of pain and symptom management.

[8]  M. Makin Subcutaneous methadone in terminally-ill patients. , 1999, Journal of pain and symptom management.

[9]  P. Mathew,et al.  Subcutaneous methadone in terminally ill patients: manageable local toxicity. , 1999, Journal of pain and symptom management.

[10]  C. Mann Patient-controlled analgesia in cancer pain , 2007 .

[11]  C. Centeno,et al.  Intermittent subcutaneous methadone administration in the management of cancer pain. , 2005, Journal of pain & palliative care pharmacotherapy.

[12]  E. Bruera,et al.  Opioid Type and Other Clinical Predictors of Laxative Dose in Advanced Cancer Patients: A Retrospective Study , 2000 .